CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

HIV Glasgow 2022

HIV Drug Therapy Glasgow 2022

October 23 - 26, 2022 
Hybrid

  • Cabotegravir

    Borch J, et al.

    6-Month outcomes of every 2-months long-acting cabotegravir and rilpivirine in a real-world setting – effectiveness, adherence to injections and patient reported outcomes from PLHIV in the German CARLOS cohort. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Chounta V, et al.

    Patient-reported outcomes after 152 weeks of HIV maintenance therapy with long-acting cabotegravir + rilpivirine in the phase 3b ATLAS-2M study. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Elliot E, et al.

    Drug-related neuropsychiatric adverse events across phase 3/3b studies of long-acting cabotegravir + rilpivirine through Week 48. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Latham C, et al.

    HIV-1 RNA blips, low-level viral replication and mean CD4+/CD8+ ratio during phase 3 cabotegravir + rilpivirine long-acting study (FLAIR) are similar to oral 3-drug therapy through Week 96. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Lutz T, et al.

    Perceptions of cabotegravir and rilpivirine long-acting (CAB+RPV LA) from patients in the CAB+RPV Implementation Study in European Locations (CARISEL). Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually. Poster Presentation. (poster only) (poster + author audio)

    View Poster

    Orkin C, et al.

    Expanded multivariable models to assist patient selection for long-acting cabotegravir+rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure over 152 weeks. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Scherzer J, et al.

    The implementation of every 2-months cabotegravir and rilpivirine long-acting injections from the perspective of healthcare providers in the German CARLOS cohort, 6-month outcomes. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Slama L, et al.

    Overcoming barriers and achieving optimal implementation of cabotegravir and rilpivirine long-acting (CAB+RPV LA): staff study participant (SSP) results from the CAB+RPV Implementation Study in European Locations (CARISEL). Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    van Welzen BJ, et al.

    Implementation of cabotegravir and rilpivirine long-acting (CAB+RPV LA): primary results from the CAB+RPV Implementation Study in European Locations (CARISEL). Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

  • Dolutegravir

    Álvarez H, et al.

    Initial plasma HIV-1 RNA and CD4+ T-cell count are determinants of virological outcomes with initial integrase inhibitor-based regimens: a prospective multinational RESPOND cohort consortium. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Beer D, et al.

    2 Year outcomes of dolutegravir (DTG) + lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    De Wit S, et al.

    Durable efficacy of switching from a 3-/4-drug tenofovir alafenamide (TAF)-based regimen to the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through Week 196. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    di Giambenedetto S, et al.

    Real-world experience with the 2-drug regimen dolutegravir and lamivudine in women with HIV: a systematic literature review. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Henegar C, et al.

    Treatment-emergent integrase inhibitor resistance among pediatric and adolescent HIV-1 populations: a systematic review. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Kabra M, et al.

    Effectiveness of dolutegravir + lamivudine in real-world studies in people with HIV-1 with M184V/I mutations: a systematic review and meta-analysis. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Kumar P, et al.

    Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in Black and Asian participants from TANGO and SALSA: pooled 48-week data analyzed by race. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Kuznetsov S, et al.

    Real-world data from the prospective, multicenter study on the use of dolutegravir-based regimens (DBRs) in ART-naive and experienced people living with HIV: 12-months results from the Russian TESLA study. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Letang E, et al.

    Lipid changes in real-world studies with the 2-drug regimen dolutegravir and lamivudine (DTG + 3TC) in people with HIV-1: a systematic literature review. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Oglesby A, et al.

    Patient-reported symptom outcomes following DTG/3TC use in a test and treat setting: results from the STAT study. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Pierone G, et al.

    Real world use of dolutegravir/lamivudine in treatment naive people living with HIV during the COVID pandemic. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually. Poster Presentation. (poster only) (poster + author audio)

    View Poster

    Prakash M, et al.

    Efficacy and safety of switching to dolutegravir plus rilpivirine in virologically suppressed older PLWH: pooled Week 148 results from SWORD-1 and SWORD-2. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Rolle CP, et al.

    High efficacy of dolutegravir/lamivudine (DTG/3TC) in treatment-naive adults with HIV-1 and high baseline viral load (VL): 48-week subgroup analyses of the GEMINI-1/-2 and STAT trials. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Schabaz F, et al.

    3-Year outcomes of dolutegravir/rilpivirine in virologically suppressed PLHIV: real-world data from the prospective German JUNGLE cohort. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Slim J, et al.

    Systematic literature review of real-world experience with the 2-drug regimen dolutegravir and lamivudine in people with HIV who would not have met inclusion criteria for the phase 3 clinical program (encore). Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

  • Fostemsavir

    Aberg J, et al.

    Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: Week 240 results of the phase 3 BRIGHTE study (encore). Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Gartland M, et al.

    A multivariable analysis of the phase 3 BRIGHTE trial, through Week 24, to identify predictors of virologic response to fostemsavir in heavily treatment-experienced people living with HIV. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Patel S, et al.

    Fostemsavir and QT prolongation: clinical applications for co-administration with other agents. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

  • Disease State

    Zhang Y, et al.

    Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Clark A, et al.

    Age related differences in quality of life outcomes of people living with HIV. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

    Leone P, et al.

    VH3810109 (N6LS) reduces viremia across a range of doses in ART-naive adults living with HIV: proof of concept achieved in the phase IIa BANNER (207959, NCT04871113) study. Presented at HIV Glasgow 2022, October 23-26, 2022, Glasgow, UK and virtually.

    View Poster

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

My MSL

Kelli Cole
Kelli Cole

Medical Science Liaison

Kelli is available in the Ohio area. If this is not your area, enter a zip code to find your MSL contact